Clinical Trial Update: Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Wharton's Jelly-derived mesenchymal stem cells for management of Retinitis Pigmentosa and inherited retinal dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Retinal Dystrophy
• Retinitis Pigmentosa

Drugs mentioned

• Wharton's Jelly Derived Mesenchymal Stem Cells (mesenchymal stem cells)

Snippet

Sponsor: Ankara Universitesi Teknokent | Conditions: Retinitis Pigmentosa, Inherited Retinal Dystrophy | Phase 3 | Status: COMPLETED